Infliximab and the risk of latent viruses reactivation in active Crohn's disease.
Lavagna A, Bergallo M, Daperno M, Sostegni R, Costa C, Leto R, Crocellà L, Molinaro G, Rocca R, Cavallo R, Pera A.
Lavagna A, et al. Among authors: costa c.
Inflamm Bowel Dis. 2007 Jul;13(7):896-902. doi: 10.1002/ibd.20131.
Inflamm Bowel Dis. 2007.
PMID: 17345605